… to compare the efficacy and safety of two recently developed biosimilars of pegfilgrastim, a
… filgrastim with those of the reference pegfilgrastim. We retrospectively analyzed data from …

… treatment were both lower in the pegteograstim group, with borderline significance. Recently,
a study comparing pegfilgrastim and its biosimilars (ie, tripegfilgrastim and pegteograstim) …

… Development of oncology biosimilars such as biosimilar pegfilgrastim could benefit patients
by increasing access to biologic agents which has the potential to improve clinical outcomes…

… safety data for Sandoz proposed biosimilar pegfilgrastim across … biosimilar or reference
pegfilgrastim (Neulasta ® ; EudraCT number 2015-003752-51) [23]. The other studies were two …

… prophylaxis in South Korea include pegfilgrastim, lipegfilgrastim, pegteograstim, and
tripegfilgrastim. These agents are known to have comparable efficacy and safety [Citation19–21]. …

… The residual uncertainty of safety, immunogenicity, and efficacy of biosimilars that has …
Biosimilar filgrastims The first biosimilar filgrastim was approved in 2008 and the first pegfilgrastim …

… In this study, a fixed dose of 6 mg tripegfilgrastim, DA-3031, … A Korean study using
pegteograstim or reference pegfilgrastim … The use of biosimilar pegfilgrastim is now widely …

… The Phase I/II study provided supportive data in patients with breast cancer for biosimilar …
efficacy and safety between pegfilgrastim reference products and pegfilgrastim biosimilars …

… No deaths were reported in patients who received pegfilgrastim PP in this study [Citation36].
Matsuda et al. reported all-cause hospital deaths in 94 (2.7%) patients, with a median …

Com o aumento da esperança média de vida e dos cuidados médico-veterinários prestados
aos animais de companhia, tem-se observado um crescimento do número de pacientes …